Roche is making significant advancements in the field of oncology with its innovative dual CAR-T program targeting CD19 and CD20 for the treatment of B-cell malignancies.

Advancements in Oncology

This initiative is part of Roche's broader strategy to enhance its bispecific portfolio.

Promising Results for Lunsumio

The subcutaneous formulation of Lunsumio, a CD20xCD3 T-cell engager, has shown promising results and may position Roche favorably against competitors like AbbVie and Genmab.

Comparable Performance in Treating Follicular Lymphoma

Recent trial data indicates that the subcutaneous version of Lunsumio performs comparably to the intravenous version in treating follicular lymphoma.

Exceeding Expectations in Drug Delivery and Patient Outcomes

The subcutaneous formulation of Lunsumio not only meets but potentially exceeds expectations in terms of drug delivery and patient outcomes.

Advantages of Subcutaneous Lunsumio

The safety profile of subcutaneous Lunsumio is also advantageous, with lower rates of adverse events and cytokine release syndrome compared to the intravenous formulation.

Competition in the Market

Roche faces competition from AbbVie and Genmab, who have already introduced their subcutaneous Epkinly into the market.

Commitment to Advancing Oncology Portfolio

Roche's commitment to advancing its oncology portfolio is demonstrated by its recent acquisition of Poseida Therapeutics.

Regulatory Approvals and Trials

Roche is actively pursuing regulatory approvals and conducting trials to ensure its offerings remain competitive.